{"id":"W2896515906","doi":"10.1093/annonc/mdy283.073","title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Bladder cancer; Cystectomy; Internal medicine; Population; Urology; Carcinoma in situ; Oncology; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001383329,0.0009990152,0.001051087,0.0001876691,0.0003357138,0.000658586,0.0006192747,0.001031342,0.003990197],"category_scores_gemma":[0.0006498822,0.0003345202,0.0007323969,0.0002946654,0.000439971,0.0005175348,0.0003458999,0.0020691,0.0007906039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008393087,"about_ca_system_score_gemma":0.001247359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007630181,"about_ca_topic_score_gemma":0.001968258,"domain_scores_codex":[0.9997903,0.00009342952,0.00001408311,0.00003739689,0.00002212856,0.00004274685],"domain_scores_gemma":[0.9996952,0.00004872542,0.0000606285,0.00002416525,0.0000239471,0.0001473922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7998182,0.02970174,0.007822282,0.002643221,0.001795213,0.0003852925,0.0002434093,0.002093134,0.0299964,0.0005041273,0.01098102,0.114016],"study_design_scores_gemma":[0.8124523,0.1656065,0.01175586,0.0001210347,0.0006890488,0.0004047299,0.00004882205,0.0009222848,0.00247051,0.0002584359,0.005256064,0.00001447389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810748,0.005069172,0.0006067789,0.0008575952,0.0001518152,0.004806326,0.003101589,0.00008869849,0.004243318],"genre_scores_gemma":[0.9807315,0.003690901,0.001330085,0.001667577,0.0001961692,0.00399615,0.004722027,0.00001833468,0.003647145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003990197,"threshold_uncertainty_score":0.01334858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08749010236186354,"score_gpt":0.4272855037666303,"score_spread":0.3397954014047668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}